(Hypertension. 1999;33:318-322.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
From the Cardiovascular Center, Weill Medical College, Cornell University, New York, NY.
Correspondence to Daniel F. Catanzaro, PhD, Cardiovascular Center, Weill Medical College, Cornell University, 1300 York Ave, Room A863, New York, NY 10021. E-mail dfcatanz{at}mail.med.cornell.edu
| Abstract |
|---|
|
|
|---|
Key Words: renin angiotensinogen kidney mice gene expression renin-angiotensin system
| Introduction |
|---|
|
|
|---|
Transgenic mice provide the opportunity to study human renin
hREN gene expression in its native cellular environment.
Moreover, the species specificity of the reaction between renin and its
substrate prevents human renin from exerting a
physiological effect unless human
angiotensinogen (AGT) is also present. In recent years,
a number of transgenic mice and rats expressing both REN and
hAGT genes have been created (Table 1
). In lines in which plasma
levels of human renin and human AGT were both elevated, plasma renin
activities increased, and the animals became
hypertensive.1 2 3
|
But are the elevated blood pressure and high plasma renin levels in these animals physiologically appropriate?
Normally, renin is released from the kidney when blood pressure falls or when the sodium chloride load sensed by the macula densa cells of the kidney is reduced. The angiotensin (Ang) II generated by the renin constricts the vasculature and promotes sodium retention, thus reestablishing blood pressure and plasma electrolytes. In so doing, the normal servo control mechanisms suppress renin secretion that is no longer required. Thus, high plasma renin activity (PRA) in the presence of high blood pressure is abnormal, suggesting a defect in the mechanisms that regulate human renin secretion in existing transgenic models.
Although all the previously developed human renin transgenic lines synthesize human renin in renal juxtaglomerular cells, they also express the hREN gene at a number of unusual extrarenal sites, such as adipose, intestines, spleen, stomach, and skeletal muscle.4 5 6 7 We recently showed in 1 of these lines that human renin is secreted into the plasma from tissues other than the kidneys.7 These extrarenal sites presumably lack the mechanisms to correctly modulate renin secretion in response to physiological changes. Thus, even though human renin secretion from the kidneys might respond appropriately,8 inappropriate secretion from extrarenal sites would maintain an elevated blood pressure.
We recently developed new transgenic mouse lines that contain 45-kb
human renin genomic sequences7 with much longer 5'- and
3'-flanking DNA sequences (
20 and
8 kb, respectively) than
previous models.4 5 In these mice, human renin mRNA is
expressed at few, mainly normal, extrarenal sites; more importantly,
circulating human renin is secreted exclusively by the kidneys.
Circulating human renin in these mice also responds appropriately (in
parallel with the endogenous mouse renin) to changes in
dietary sodium, converting enzyme inhibition and ß-adrenergic
stimulation.9 Moreover, infusion of mouse or human AGT
results in an increase in blood pressure that suppresses both human and
mouse renin secretion in these animals.9
In the present study, we investigated the effect of making 45-kb hREN mice doubly transgenic for the hAGT gene. Mice carrying a hAGT transgene10 have 4 to 5 times the normal human levels of human AGT circulating in their plasma. In contrast to previous studies, we show that the doubly transgenic mice are normotensive and that their plasma levels of human and mouse renins are suppressed. This results in a constant PRA that is consistent with their normotension. These studies demonstrate the importance of correct cell- and tissue-specific renin gene expression in maintaining normal blood pressure and affirm the pivotal role played by renal renin secretion in blood pressure control.
| Methods |
|---|
|
|
|---|
We prepared 45-kb hREN transgenic mice using a 45-kb Not ISal I fragment from the P1 human renin genomic clone number 396911 as described.7 The original founder mice were back-crossed to C57BL6 through 4 or 5 generations. hAGT mice containing a 14-kb hAGT genomic fragment10 were obtained from Jackson Labs. Transgenic animals were identified by Southern blotting of DNA extracted from tail tips. Mice were housed under standard conditions with free access to tap water and Formulab mouse chow (No. 5008, containing 0.28% sodium).
Blood samples (
200 µL) were obtained by orbit sinus puncture and
assayed for mouse and human renin, total renin, and AGT as
described.9 However, the concentration of human substrate
in the hPRC assay was increased 6-fold to a level close to
Km. PRA was determined by incubating 75
µL of plasma for 3 hours at 37°C with an equal volume of buffer (pH
5.6) containing 3 mmol/L EDTA and 0.04% phenylmethylsulfonyl
fluoride.12
Blood pressure was measured with a Visitech 2000 automated tail-cuff sphygmomanometer. Blood pressure measurements were routinely carried out between 9 AM and noon. Animals were acclimated to the tail cuff and measurement procedure for 3 days, after which consistent blood pressure measurements were obtained. Animals were routinely subjected to 5 preliminary cycles and 10 measurement cycles. Usually, >70% of cycles yielded a measurement. The SE for each set of 10 measurement cycles was typically>10% of the mean.
In a sampling of mice from all the transgenic litters generated in this study, blood pressure was also measured directly while the mice were conscious. Blood pressures were measured by tail cuff in the morning. The mice were then catheterized and allowed to recover, and direct measurements were taken in the afternoon or on the following day. There was a strong correlation between systolic blood pressure measured by tail cuff (TC) and mean arterial pressure (MAP) measured directly: MAP=5.8+0.9(TC); r2=0.54; range, 90 to 120 mm Hg; n=8.
Statistical Analysis
All values are expressed as mean±SEM. Comparisons between mouse
and human renin and AGT measurements and blood pressure and heart rate
measurements for the 4 possible transgenic genotypes were
tested by ANOVA. The significance of multiple comparisons was assessed
by Scheffé's test. A value of P<0.05 was considered
statistically significant.
| Results |
|---|
|
|
|---|
2=1.11, P=NS). All animals
developed normally and reached similar weights for their sex (data not
shown).
Blood Pressure
Blood pressure measurements were begun at 4 weeks of age, and
blood samples were drawn at 4 and 8 weeks. In all mice, regardless of
their transgenic genotype, blood pressure and heart rate
remained normal (Table 2
).
|
Plasma Levels of Human and Mouse Renin and AGT
In the present study, in singly transgenic 45-kb
hREN mice, human plasma renin concentration (PRC) averaged
98±12 ng Ang I · mL-1 ·
h-1, and human plasma total renin concentration
(TRC) averaged 156±18 ng Ang I ·
mL-1 · h-1. In
nontransgenic mice, mouse TRC averaged 1314±217 ng Ang I ·
mL-1 · h-1, and
mouse PRC averaged 850±179. Normal human PRC is typically
10 ng Ang
I · mL-1 ·
h-1. The extraordinarily high mouse levels are
similar to results from our earlier study and reports from other
laboratories. Normal plasma levels of renin-angiotensin
system components in mice and humans are reviewed
elsewhere9 Measurements of human PRC and TRC were
higher than previously reported9 because of the higher
substrate concentration used in assays for the present study.
Nevertheless, in the present study, the proportion of total renin
secreted as active renin was 62% for human and 65% for mouse, which
are also very similar to our previous report (57% and 63% for human
and mouse renins, respectively).9 As described previously,
mouse PRC was lower in hREN mice than in control mice,
although these differences were not significant at either time
point.
Most importantly, hREN mice that carried the hAGT
gene had lower human and mouse PRC compared with singly transgenic
hREN mice (the Figure
). In the doubly
transgenic mice, human PRC was suppressed 3.2-fold at 2 weeks and
2.3-fold at 4 weeks, relative to singly transgenic hREN
mice. Mouse PRC was suppressed even further, by 5.2-fold at 1 month and
7.3-fold at 2 months. In doubly transgenic animals, plasma levels of
human AGT remained relatively constant between 4 and 8 weeks, ranging
from 4000 to 4500 ng Ang I · mL-1
· h-1, which is about 5 times the normal human
level. There were no significant differences in plasma levels of human
AGT between animals that carried only the hAGT transgene and
those that also carried the hREN transgene.
|
In 1 group of mice, PRA levels were determined at 8 weeks of age. PRA is the ability of plasma to generate Ang I and reflects the plasma concentration of both renin and AGT. Despite the differences in mouse and human PRC and substrate levels, PRA levels were remarkably similar in all animals, regardless of their transgenic type (range, 20 to 40 ng Ang I · mL-1 · h-1). This suggests that renin secretion changed in response to differences in AGT to maintain a constant rate of angiotensin formation.
Although not directly related to the major conclusions of this study, there are a number of additional noteworthy observations. First, mouse AGT levels were determined by the ability of hog renin to generate Ang I from mouse plasma. Although hog renin does not significantly cleave human AGT, the rate of Ang I generation from the plasma of animals carrying the hAGT transgene was 2- to 3-fold higher than animals expressing only the endogenous mAGT gene. Mouse AGT levels also appeared to be lower in animals expressing the hREN transgene. One possible explanation for this finding is that human renin may bind mouse AGT without cleaving it, thus acting as a competitor for mouse renin. Second, human TRC did not differ significantly between doubly transgenic mice and mice carrying hREN alone. However, mouse TRC was suppressed 1.8-fold at 1 month and 2.3-fold at 2 months, although both differences were at the borderline of significance. These data suggest that mouse prorenin in the plasma is derived largely from the kidney, whereas human prorenin is largely from extrarenal sources.
| Discussion |
|---|
|
|
|---|
Although plasma levels are determined primarily by secretory mechanisms controlling the release of stored renin, mechanisms regulating renin gene expression may also contribute to the determination of the amount of renin and prorenin release. In this respect, the longer transgene may contain additional regulatory sequences that may affect basal levels, responses to physiological stimuli, or both.
Human plasma renin levels were similar in 45-kb hREN mice and in hREN lines used in the 2 previous mouse models2 3 7 9 (30 to 50 ng Ang I · mL-1 · h-1). However, in 45-kb hREN mice doubly transgenic for hAGT, PRA was unchanged and hPRC was suppressed up to 3.2-fold. In contrast, in the other 2 lines, PRA was highly elevated in the doubly transgenic mice. Although in 1 of these lines human PRC was suppressed about 2.3-fold, PRA remained high,2 suggesting that suppression of human PRC was inadequate. The latter observation is consistent with findings that human renin is expressed in renal juxtaglomerular cells of all transgenic lines. Although this component of circulating renin may be normally regulated, plasma human renin secreted from extrarenal sites is unlikely to respond to increases in blood pressure or Ang II and remains elevated.
It is noteworthy that we used the same hAGT line as 1 of the previous studies.3 Although plasma levels of human renin and human AGT were similar in the singly transgenic lines, only the 45-kb hREN mice were able to suppress human renin and remain normotensive. Thus, the reason that mice made doubly transgenic for the 13-kb hREN transgene became hypertensive was not overexpression of the human renin angiotensin system per se but rather their inability to suppress renin secretion when their blood pressure rose as a result of the excess angiotensin that was generated.
It is unlikely that the level of AGT plays a significant role in the present model. Although in normal human plasma AGT circulates at levels close to the Km for its reaction with renin, it is the level of renin that changes rapidly in response to physiological perturbations affecting blood pressure and electrolyte balance. Any increase in AGT should feed back to the kidney to suppress renin secretion.
Human AGT levels in the 14-kb hAGT line were about 5-fold higher than normal levels in human plasma. This is similar to the elevated substrate levels observed in many women taking oral contraceptives.13 Despite the elevated substrate, these women remain normotensive, presumably because their plasma renin levels are suppressed through the normal feedback mechanism. Therefore, it is surprising that the M235T mutation in the human AGT gene14 that appears to be associated with a mere 15% increase in plasma AGT levels should confer an increased risk for hypertension, unless there were some concomitant defect in the mechanisms that regulate renin secretion in these individuals. In this respect, 1 study of the M235T polymorphism that measured PRC rather than PRA levels reported a suppression of PRC in subjects with elevated AGT but found no association of plasma AGT levels with blood pressure.15
Another study that has implicated a role for AGT in hypertension is the
demonstration that titration of plasma AGT levels in mice by gene
targeting causes proportional changes in blood
pressure.16 17 Although plasma renin levels in mice are
exceptionally high, mouse AGT circulates at a level
40-fold lower
that in most other species, including humans, with the result that PRA
in mice is the same as in other species. However, with limiting
concentrations of AGT, the rate of angiotensin formation in
mice is more sensitive to changes in substrate concentration than other
species, and mice may not be able to regulate their enormous plasma
renin levels sufficiently to compensate for changes in substrate
concentration. Thus, the substrate dependence of blood pressure
observed in AGT knockout mice may be a peculiarity of the mouse
renin-angiotensin system.
In addition to the actual level of AGT, the present study suggests that the tissue source of AGT may not be as important as that of renin. In each of the hAGT transgenic lines used to prepare the doubly transgenic animals, hAGT mRNA was detected in a number of unusual tissues, such as the heart,1 10 18 lung, and ovary10 18 and skeletal muscle,1 sites where AGT is not normally expressed. Nonetheless, if human renin is appropriately regulated, these mice remain normotensive.
In summary, transgenic mice containing an hREN gene fragment with long flanking sequences express human renin in a physiologically appropriate manner. When these mice are mated with mice carrying the human AGT gene, the doubly transgenic offspring that express both human renin and human AGT are normotensive, despite high levels of human renin and human AGT in the singly transgenic parental lines. This results because both human and mouse renins are suppressed to maintain a normal PRA.
The significance of this finding is best understood in relation to the role of the kidneys in maintaining blood pressure. The kidneys maintain a constant blood pressure by excreting or retaining sodium as needed. Sodium excretion in turn is regulated by the renin-angiotensin-aldosterone system. Therefore, as long as renin is synthesized and secreted appropriately by the kidneys and adequate amounts of salt are available, normal renal function determines blood pressure, and the activity of the renin-angiotensin system is suppressed. Only when renin secretion escapes normal renal controls will the renin-angiotensin system interfere with normal renal regulation of blood pressure.
| Acknowledgments |
|---|
Received September 16, 1998; first decision October 16, 1998; accepted November 2, 1998.
| References |
|---|
|
|
|---|
2.
Fukamizu A, Sugimura K, Takimoto E, Sugiyama F, Seo
M-S, Takahashi S, Hatae T, Kajiwara N, Yagami K-I, Murakami K. Chimeric
renin-angiotensin system demonstrates sustained increase in
blood pressure of transgenic mice carrying both human renin and human
angiotensinogen genes. J Biol Chem. 1993;268:1161711621.
3. Merrill DC, Thompson MW, Carney CL, Granwehr BP, Schlager G, Robillard JE, Sigmund CD. Chronic hypertension and altered baroreflex responses in transgenic mice containing the human renin and human angiotensinogen genes. J Clin Invest. 1996;97:10471055.[Medline] [Order article via Infotrieve]
4.
Sigmund CD, Jones CA, Kane CM, Wu C, Lang JA, Gross
KW. Regulated tissue- and cell-specific expression of the human renin
gene in transgenic mice. Circ Res. 1992;70:10701079.
5. Fukamizu A, Seo MS, Hatae T, Yokoyama M, Nomura T, Katsuki M, Murakami K. Tissue-specific expression of the human renin gene in transgenic mice. Biochem Biophys Res Commun. 1989;165:826832.[Medline] [Order article via Infotrieve]
6.
Ganten D, Wagner J, Zeh K, Bader M, Michel JB, Paul M,
Zimmerman F, Ruf P, Hilgefeldt U, Ganten U, Kaling M, Bachman S,
Fukamizu A, Mullinins JJ, Murakami K. Species specificity of renin
kinetics in transgenic rats harboring the human renin and
angiotensinogen genes. Proc Natl Acad Sci
U S A. 1992;89:78067810.
7.
Yan Y, Chen R, Pitarresi T, Sigmund CD, Gross KW,
Sealey JE, Laragh JH, Catanzaro DF. Kidney is the only source of human
plasma renin in 45 kb hREN transgenic mice. Circ Res. 1998;83:12791288.
8.
Thompson MW, Smith SB, Sigmund CD. Regulation of human
renin mRNA expression and protein release in transgenic mice.
Hypertension. 1996;28:290296.
9.
Yan Y, Hu L, Chen R, Laragh JH, Sealey JE, Catanzaro
DF. Appropriate regulation of human renin gene expression and secretion
in 45 kb human renin transgenic mice. Hypertension. 1998;32:205214.
10.
Yang G, Merrill DC, Thompson MW, Robillard JE, Sigmund
CD. Functional expression of the human angiotensinogen gene
in transgenic mice. J Biol Chem. 1994;269:3249732502.
11.
Yan Y, Jones CA, Sigmund CD, Gross KW, Catanzaro DF.
Conserved enhancer elements in human and mouse renin genes have
different transcriptional effects in As4.1 cells. Circ Res. 1997;81:558566.
12.
Sealey JE. Plasma renin activity and plasma prorenin
assays. Clin Chem. 1991;37:18111819.
13. Goldhaber SZ, Hennekens CH, Spark RF, Evans DA, Rosner B, Taylor JO, Kass EH. Plasma renin substrate, renin activity, and aldosterone levels in a sample of oral contraceptive users from a community survey. Am Heart J. 1984;107:119122.[Medline] [Order article via Infotrieve]
14. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992;71:169180.[Medline] [Order article via Infotrieve]
15.
Bennett CL, Schrader AP, Morris BJ. Cross-sectional
analysis of Met235
Thr variant of
angiotensinogen gene in severe, familial hypertension.
Biochem Biophys Res Commun. 1993;197:833839.[Medline]
[Order article via Infotrieve]
16.
Smithies O, Kim HS. Targeted gene duplication and
disruption for analyzing quantitative genetic traits in mice.
Proc Natl Acad Sci U S A. 1994;91:36123615.
17.
Kim HS, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB,
Best CF, Jennette JC, Coffman TM, Maeda N, Smithies O. Genetic control
of blood pressure and the angiotensinogen locus. Proc
Natl Acad Sci U S A. 1995;92:27352739.
18. Takahashi S, Fukamizu A, Hasegawa T, Yokoyama M, Nomura T, Katsuki M, Murakami K. Expression of human angiotensinogen gene in transgenic mice and in transfected cells. Biochem Biophys Res Commun. 1991;180:11031109.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
B. C Cholewa and D. L Mattson Influence of elevated renin substrate on angiotensin II and arterial blood pressure in conscious mice Exp Physiol, July 1, 2005; 90(4): 607 - 612. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Xia, H. Wen, H. R. Prashner, R. Chen, T. Inagami, D. F. Catanzaro, and R. E. Kellems Pregnancy-Induced Changes in Renin Gene Expression in Mice Biol Reprod, January 1, 2002; 66(1): 135 - 143. [Abstract] [Full Text] |
||||
![]() |
B. C. Cholewa and D. L. Mattson Role of the renin-angiotensin system during alterations of sodium intake in conscious mice Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2001; 281(3): R987 - R993. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. PRESCOTT, D. W. SILVERSIDES, S. M. L. CHIU, and T. L. REUDELHUBER Contribution of circulating renin to local synthesis of angiotensin peptides in the heart Physiol Genomics, November 9, 2000; 4(1): 67 - 73. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Bohlender, J. Menard, D. Ganten, and F. C. Luft Angiotensinogen Concentrations and Renin Clearance : Implications for Blood Pressure Regulation Hypertension, March 1, 2000; 35(3): 780 - 786. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. L. Sinn, D. R. Davis, and C. D. Sigmund Highly Regulated Cell Type-restricted Expression of Human Renin in Mice Containing 140- or 160-Kilobase Pair P1 Phage Artificial Chromosome Transgenes J. Biol. Chem., December 10, 1999; 274(50): 35785 - 35793. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Morimoto, M. D. Cassell, and C. D. Sigmund The Brain Renin-Angiotensin System in Transgenic Mice Carrying a Highly Regulated Human Renin Transgene Circ. Res., January 11, 2002; 90(1): 80 - 86. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |